信达生物(01801.HK)股价吐3.7% 拟折让4.7%配新股兼遭主席减持
信达生物(01801.HK)拟折让近4.7%配5,620万股新股兼遭主席减持3,680万股,该股连吐第二天,今天曾略失配股价50元,低见49.95元,现造50.5元,续吐3.7%,成交受市前两宗合共3,680万股P盘以每股50元上板带动急增至5,260万股,涉资26.38亿元。
信达生物拟以每股50元(较昨天收市价折让约4.7%),配售5,620万股新股或占扩大後股本4.02%,净筹27.88亿元。另外,公司主席兼首席执行官俞德超亦以同价配售3,680万股,套现18.4亿元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.